



## URKUNDE

Es wird hiermit bescheinigt,  
dass für die in der Patentschrift  
beschriebene Erfindung ein  
europäisches Patent für die in der  
Patentschrift bezeichneten Ver-  
tragsstaaten erteilt worden ist.

## CERTIFICATE

It is hereby certified that a  
European patent has been granted  
in respect of the invention  
described in the patent specifica-  
tion for the Contracting States  
designated in the specification.

## CERTIFICAT

Il est certifié qu'un brevet  
européen a été délivré pour  
l'invention décrite dans le  
fascicule de brevet, pour les  
Etats contractants désignés  
dans le fascicule de brevet.

Europäisches Patent Nr.

European patent No.

Brevet européen n°

**2538918**

Patentinhaber

Proprietor of the patent

Titulaire du brevet

**Omikron Italia S.r.L.**  
Viale Bruno Buozzi 5  
00197 Rome/IT

**Benoît Battistelli**

Präsident des Europäischen Patentamts  
President of the European Patent Office  
Président de l'Office européen des brevets

München, den  
Munich,  
Fait à Munich, le

**19.11.14**

(19)



(11)

**EP 2 538 918 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:  
**19.11.2014 Bulletin 2014/47**

(51) Int Cl.:  
**A61K 9/00 (2006.01) A61K 31/7068 (2006.01)**

(21) Application number: **11711656.6**

(86) International application number:  
**PCT/IB2011/050663**

(22) Date of filing: **17.02.2011**

(87) International publication number:  
**WO 2011/101802 (25.08.2011 Gazette 2011/34)**

(54) **CITICOLINE FOR THE TREATMENT OF GLAUCOMA**

CITICOLIN ZUR BEHANDLUNG VON GLAUKOM

CITICOLINE DANS LE TRAITEMENT DU GLAUCOME

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

(74) Representative: **Germinario, Claudio et al Società Italiana Brevetti S.p.A. Piazza di Pietra, 38-39 00186 Roma (IT)**

(30) Priority: **22.02.2010 IT RM20100071**

(56) References cited:  
 • **OSHITARI T ET AL: "Citicoline has a protective effect on damaged retinal ganglion cells in mouse culture retina", NEUROREPORT 20021115 GB, vol. 13, no. 16, 15 November 2002 (2002-11-15), pages 2109-2111, XP008127625, ISSN: 0959-4965 cited in the application**

(43) Date of publication of application:  
**02.01.2013 Bulletin 2013/01**

(73) Proprietor: **Omikron Italia S.r.L. 00197 Rome (IT)**

Remarks:  
 The file contains technical information submitted after the application was filed and not included in this specification

(72) Inventors:  
 • **VIRNO, Cristiano I-00197 Rome (IT)**  
 • **MALIZIA, Marco I-00144 Rome (IT)**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 538 918 B1**